Results 1 to 10 of about 80,610 (161)

Chronic myeloid leukemia presenting with isolated central nervous system lymphoid blast crisis: A case report [PDF]

open access: yesRare Tumors
Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the Philadelphia chromosome, typically progressing through chronic, accelerated, and blast phases. Blast crisis may be myeloid or lymphoid.
Álvaro Zarama-Valenzuela   +3 more
doaj   +2 more sources

Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations

open access: yesPharmaceutics, 2021
Cancer is still a major barrier to life expectancy increase worldwide, and hematologic neoplasms represent a relevant percentage of cancer incidence rates.
Caio Bezerra Machado   +10 more
doaj   +1 more source

DETECTION OF BCR-ABL PROTEIN IN CHRONIC MYELOID LEUKEMIA PATIENTS USING IMMUNOCYTOCHEMISTRY

open access: yesThe Iraqi Journal of Medical Sciences, 2016
Background: Chronic Myeloid leukemia (CML) is a myeloproliferetive disorder associated with chromosomal abnormality, Philadelphia chromosome (Ph), in more than 95% of CML patients. The resulting BCR-ABL fused gene is markers for this type of leukemia. In
Maysaa Abdul Razaq Dhahi   +2 more
doaj   +6 more sources

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]

open access: yes, 2014
Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M   +6 more
core   +5 more sources

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors

open access: yesHaematologica, 2018
Diseases with clonal hematopoiesis such as myelodysplastic syndrome and acute myeloid leukemia have high rates of relapse. Only a small subset of acute myeloid leukemia patients are cured with chemotherapy alone. Relapse in these diseases occurs at least
Rajeswaran Mani   +18 more
doaj   +1 more source

Hemostatic and thrombotic parameters in acure leukemia- A comparison of pre and post remission induction phase

open access: yesLiaquat Medical Research Journal, 2022
This study was aimed to compare hemostatic, fibrinolytic and thrombotic parameters in pre and post induction chemotherapy in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL).
Tehmina Nafees Sonia Khan   +5 more
doaj   +1 more source

Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML [PDF]

open access: yes, 2002
HTIF1α, a transcription coactivator which is able to mediate RARα activity and functionally interact with PML, is encoded by a gene on chromosome 7q32–34, which is a critical region in acute myeloid leukemias (AML). With the assumption that this gene may
AGUIARI, Gianluca   +8 more
core   +1 more source

Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase

open access: yesClinical Medicine Insights: Oncology, 2022
Despite the major advancements in the management of chronic phase (CP) chronic myeloid leukemia (CML), blast crisis (BC) remains a major therapeutic challenge. BC can be myeloid, lymphoid, or mixed lineage with myeloid BC being the most common type.
Binoy Yohanan, Binsah George
doaj   +1 more source

Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis [PDF]

open access: yes, 2016
Myeloid leukaemias share the common characteristics of being stem cell-derived clonal diseases, characterised by excessive proliferation of one or more myeloid lineage.
Toofan, Parto, Wheadon, Helen
core   +1 more source

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies

open access: yesThe Journal of Clinical Investigation, 2023
The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic lymphocytic leukemia (CLL); however, resistance may develop over time.
Stephen Jun Fei Chong   +23 more
doaj   +1 more source

Home - About - Disclaimer - Privacy